1.0) Histo or cyto dx of Stage IIIa or IIIb NSCLC CA involving superior sulcus (T3-4, N0-1)
2.0) Mediastinal/Supraclavicular nodal invol (N2/N3 Dx) NOT ELIGIBLE
3.0) Parenchymal lesions = 2 same or both lungs NOT ELIGIBLE
4.0) Must have mediastinal exploration 42 days prior to registration.
5.0) No evidence of distant mets found 42 days prior to registration.
6.0) Must have measurable dz.

7.0) No prior chemo or RT allowed.
8.0) PS 0-2.

Drugs: CDDP, VP-16

9.0)
10.0)
11.0)

1.0) Pt must be randomized to this study = 5 days from randomization to S9623.
2.0) Prestudy bone marrow speciman must be submitted.

**Long term follow up study only. See SWOG website for list of Applicable Treatment Trials **

(S0221, S0307, S0800, S0812, S1310, S9921, S0925, S0033)

-Newly diagnosed primary breast cancer prior to initial definitive surgical treatment, including In situ and Invasive cancer, Stages 0 - III. Pathologic confirmation of diagnosis is required.
-Patients must be able to read and write in English or Spanish
-Patients must not have received HBOC genetic counseling or mutation testing prior to diagnosis. If the patient was previously tested only for a variant of uncertain clinical significance (i.e., not for known familial mutation, Jewish ethnicity panel/Multisite 3 or comprehensive sequencing) and documentation is provided, they remain eligible.

Due to IP storage conditions, patients should be treated in Ann Arbor only.

*Substudy cohort palbociclib/ pancreatic/ CDKN2A mutation or loss is closed to accrual

*Substudy cohort palbociclib/ gallbladder and bile ducts/ CDKN2A loss or mutation is closed. *Substudy cohort olaparib/HER2-negative metastatic breast/ deleterious (or suspected) germline BRCA-mutated is closed to accrual

*Substudy cohorts with vismodegib and erlotinib closed.

*Substudy cohort sunitinib/ colorectal/ FLT-3 mutation or amplification is suspended.
*Substudy cohort olaparib/pancreatic/germline or somatic BRCA1/2 inactivating mutations is suspended.
*Pfizer drug substudy cohorts suspended.
*Substudy cohort cetuximab/breast/ KRAS, NRAS and BRAF wildtype (all) is suspended.

-Patients with metastatic or advanced solid tumors, multiple myeloma or B cell non-Hodgkin lymphoma who have exhausted standard treatment options or for whom no standard treatment is available are eligible to participate in this study.
-A potentially actionable genomic variant must be present, as revealed by a tumor genomic test or IHC test for protein overexpression that has been previously performed on a specimen of the tumor or on cell-free DNA obtained from plasma
-ECOG PS must be 0-2
-Patients must have measurable or evaluable disease by physical or radiographic exam
-Patients must have a tumor genomic profile for which single agent treatment with one of the FDA approved targeted anti-cancer drugs included in this study has potential clinical benefit
-Patients must NOT have ongoing toxicity greater than grade 1, other than peripheral neuropathy.
-Patients must NOT have peripheral neuropathy greater than grade 3.
-Patients must not have been previously treated with the selected study drug for the same malignancy
-If disease has a genomic variant known to confer resistance to an available anti-cancer agent available, the patient is not eligible to receive it; however, the patient may be eligible for other available drugs in this study
-Patients with known active progressive brain mets are not eligible.
-Patients must meet the drug-specific inclusion and exclusion criteria defined by their genomic testing results.

*Credentialing required for each participating staff member. Please check your staff's credentialing status.*
*Check for eligibility to DCP-001

-Must be at least 70 years old
-Must have diagnosis of advanced solid tumor malignancy or lymphoma. (Stage IV or stage III if cure is not possible or anticipated).
-Must plan to start new treatment with chemo or prevalent toxicity within 4 weeks from baseline and plan to continue this treatment for at least 3 months
-Patients are allowed to receive concurrent RT
-Patients are allowed to simultaneous participate in a treatment trial
-Must have at least one geriatric assessment domain meet the cut-off score for impairment (other than polypharmacy)
-Must have understanding of English
-Must NOT have surgery planned within 3 months
-Must not have presence of CNS disease. Patients with history of treated brain mets are eligible if they are asymptomatic

*Credentialing required for each participating staff member. Please check your staff's credentialing status.*
*Check for eligibility to DCP-001*

-Patients must be at least 70 years old
-Must have diagnosis of an advanced solid tumor malignancy (stage IV or stage III if cure is not possible or anticipated)
-Must be considering or currently receiving any kind of cancer treatment. Patients with a history of previous cancer treatment are eligible.
-Must have at least 1 geriatric assessment domain meet the cut-off score for impairment (other than polypharmacy)
-Must have visits planned with oncologist for at least 3 months
-Must have adequate understanding of English
-Must not have surgery planned within 3 months
-Must not have already decided not to undergo any cancer treatment

Credentialing required. Please check your site's credentialing status.
CURRENT SITES CREDENTIALED: SJMH, Genesys Hurley, Hurley, Saginaw , St John, St. Joe Oakland, Sparrow, Holy Cross

-Have a diagnosis of breast cancer and be chemotherapy naïve. Note: Prior methotrexate for non-cancerous conditions is allowed.
-Be scheduled to receive a single-day chemotherapy regimen that contains doxorubicin and/or cyclophosphamide and/or carboplatin.
-Be scheduled to receive an antiemetic regimen that does not contain Akynzeo®.
-Be able to read English (Spanish materials not provided)
-Have ECOG performance status of 0, 1, or 2
Cycle 2

- Only participants with a nausea score > 3 at least once on the diary assessment from Cycle 1 can be randomized for Cycle 2.
-Participants must be scheduled to receive the same chemotherapy regimen as received at Cycle 1.

Participants must not:
-Have a known history of central nervous system disease
-Have uncontrolled diabetes mellitus or uncontrolled hyperglycemia.